Kwok-Ho Chan
Overview
Explore the profile of Kwok-Ho Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bond A, Craigon C, Chan K, Testa A, Karapetsas A, Fasimoye R, et al.
J Med Chem
. 2025 Jan;
68(3):3900-3901.
PMID: 39838864
No abstract available.
2.
Roth S, Kocaturk N, Sathyamurthi P, Carton B, Watt M, Macartney T, et al.
Cell Chem Biol
. 2023 Aug;
30(10):1261-1276.e7.
PMID: 37591251
Targeted protein degradation (TPD), induced by enforcing target proximity to an E3 ubiquitin ligase using small molecules has become an important drug discovery approach for targeting previously undruggable disease-causing proteins....
3.
Imaide S, Riching K, Makukhin N, Vetma V, Whitworth C, Hughes S, et al.
Nat Chem Biol
. 2021 Oct;
17(11):1157-1167.
PMID: 34675414
Bivalent proteolysis-targeting chimeras (PROTACs) drive protein degradation by simultaneously binding a target protein and an E3 ligase and forming a productive ternary complex. We hypothesized that increasing binding valency within...
4.
Bond A, Craigon C, Chan K, Testa A, Karapetsas A, Fasimoye R, et al.
J Med Chem
. 2021 Oct;
64(20):15477-15502.
PMID: 34652918
Small-molecule-induced protein depletion technologies, also called inducible degrons, allow degradation of genetically engineered target proteins within cells and animals. Here, we design and develop the BromoTag, a new inducible degron...
5.
Klein V, Townsend C, Testa A, Zengerle M, Maniaci C, Hughes S, et al.
ACS Med Chem Lett
. 2020 Sep;
11(9):1732-1738.
PMID: 32939229
Proteolysis targeting chimeras (PROTACs) are catalytic heterobifunctional molecules that can selectively degrade a protein of interest by recruiting a ubiquitin E3 ligase to the target, leading to its ubiquitylation and...
6.
Roth S, Macartney T, Konopacka A, Chan K, Zhou H, Queisser M, et al.
Cell Chem Biol
. 2020 Jul;
27(9):1151-1163.e6.
PMID: 32668202
K-RAS is known as the most frequently mutated oncogene. However, the development of conventional K-RAS inhibitors has been extremely challenging, with a mutation-specific inhibitor reaching clinical trials only recently. Targeted...
7.
Testa A, Lucas X, Castro G, Chan K, Wright J, Runcie A, et al.
J Am Chem Soc
. 2019 Apr;
141(18):7644.
PMID: 31017404
No abstract available.
8.
Testa A, Lucas X, Castro G, Chan K, Wright J, Runcie A, et al.
J Am Chem Soc
. 2018 Jun;
140(29):9299-9313.
PMID: 29949369
Hydroxylation and fluorination of proline alters the pyrrolidine ring pucker and the trans:cis amide bond ratio in a stereochemistry-dependent fashion, affecting molecular recognition of proline-containing molecules by biological systems. While...
9.
Chan K, Zengerle M, Testa A, Ciulli A
J Med Chem
. 2017 Jun;
61(2):504-513.
PMID: 28595007
The design of proteolysis-targeting chimeras (PROTACs) is a powerful small-molecule approach for inducing protein degradation. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. Here...
10.
Gadd M, Testa A, Lucas X, Chan K, Chen W, Lamont D, et al.
Nat Chem Biol
. 2017 Mar;
13(5):514-521.
PMID: 28288108
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3...